A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...

TOKYO, Japan & BASKING RIDGE, NJ, USA I 13, 2024 I Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU® (trastuzumab ...

Source: Getty Images Researchers observed positive results with ivonescimab, N-803, aumolertinib, sacituzumab govitecan, ifinatamab deruxtecan, durvalumab-based combinations, and amivantamab and ...

Ifinatamab deruxtecan has demonstrated antitumor activity as second-line or later therapy in patients with ES-SCLC.

Pharmaceutical companies are making investments in research of therapies that target three different antigen-binding sites.

Patients with pretreated extensive small cell lung cancer could benefit from the antibody-drug conjugate ifinatamab ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with the antibody drug-conjugate ifinatamab deruxtecan (I-DXd) showed promising activity in pretreated patients ...

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among ...